首页> 美国卫生研究院文献>Oncotarget >The association between clinical prognostic factors and epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) efficacy in advanced non-small-cell lung cancer patients: a retrospective assessment of 94 cases with EGFR mutations

【2h】

The association between clinical prognostic factors and epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) efficacy in advanced non-small-cell lung cancer patients: a retrospective assessment of 94 cases with EGFR mutations

机译：晚期非小细胞肺癌患者临床预后因素与表皮生长因子受体酪氨酸激酶抑制剂（EGFR-TKI）疗效的关联：回顾性评估94例EGFR突变患者

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
相似文献
相关主题

摘要

ObjectiveThis study aimed to examine the association of clinical prognostic factors with epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) efficacy in advanced non-small-cell lung cancer (NSCLC) patients.

机译：目的本研究旨在探讨晚期非小细胞肺癌（NSCLC）患者临床预后因素与表皮生长因子受体酪氨酸激酶抑制剂（EGFR-TKI）疗效的关系。

著录项

期刊名称 Oncotarget
作者
Jing-Hui Lin; Dong Lin; Ling Xu; Qiang Wang; Hui-Hua Hu; Hai-Peng Xu; Zhi-Yong He;
展开▼
作者单位

展开▼
年(卷),期 2017(8),2
年度 2017
页码 3412–3421
总页数 10
原文格式 PDF
正文语种
中图分类肿瘤学;细胞生物学;
关键词
non-small-cell lung cancer epidermal growth factor receptor epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) prognostic factor retrospective analysis;

机译：非小细胞肺癌;表皮生长因子受体;表皮生长因子受体酪氨酸激酶抑制剂（EGFR-TKI）;预后因素;回顾性分析;

相似文献

外文文献
中文文献
专利

1. Efficacy of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) combined with bevacizumab for advanced non-squamous non-small-cell lung cancer patients with gradual progression on EGFR-TKI treatment [J] . Yu Yuman, Wang Yuehong, Wu Linying, Medicine. . 2021,第5期

机译：表皮生长因子受体酪氨酸激酶抑制剂（EGFR-TKIS）与贝伐单抗进行高级非鳞状非小细胞肺癌患者的疗效对EGFR-TKI治疗逐渐进展
2. Efficacy of first-line treatment with epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) alone or in combination with chemotherapy for advanced non-small cell lung cancer (NSCLC) with low-abundance mutation [J] . Yan Xiangtao, Wang Huijuan, Li Peng, Lung cancer: Journal of the International Association for the Study of Lung Cancer . 2019,第期

机译：单独或与低丰度突变的先进非小细胞肺癌（NSCLC）组合单独使用表皮生长因子受体 - 酪氨酸激酶抑制剂（EGFR-TKI）的疗效。
3. Epidermal growth factor receptor mutations and their correlation with epidermal growth factor receptor-tyrosine kinase inhibitor therapy and association with the characteristics of patients with non-small-cell lung cancer: A meta-analysis [J] . Xiao-Hang Zhang, Cheng Li, Chen-Fei Dai, Thoracic cancer. . 2011,第3期

机译：表皮生长因子受体突变及其与表皮生长因子受体酪氨酸激酶抑制剂治疗的相关性以及与非小细胞肺癌患者特征的关联：荟萃分析
4. QSAR Study of Quinazoline Derivatives as Inhibitor of Epidermal Growth Factor Receptor-Tyrosine Kinase (EGFR-TK) [C] . La Ode Aman, Widisusanti Abdulkadir, Julitha Geybie Rembet, International Conference on Computation for Science and Technology . 2015

机译：喹唑啉衍生物作为表皮生长因子受体 - 酪氨酸激酶（EGFR-TK）抑制剂的QSAR研究
5. Predictive Biomarkers of the Efficacy of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Treating Advanced Non-small Cell Lung Cancer: A Systematic Review of Randomized Controlled Trials [D] . Yang, Zuyao. 2014

机译：表皮生长因子受体酪氨酸激酶抑制剂治疗晚期非小细胞肺癌疗效的预测生物标志物：随机对照试验的系统评价。
6. Traditional Chinese Medicine Prolongs Progression-Free Survival and Enhances Therapeutic Effects in Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI)Treated Non-Small-Cell Lung Cancer (NSCLC) Patients Harboring EGFR Mutations [O] . Mo Tang, Shumei Wang, Bin Zhao, 2019

机译：中药可延长表皮生长因子受体酪氨酸激酶抑制剂（EGFR-TKI）治疗的非小细胞肺癌（NSCLC）携带EGFR突变的患者的无进展生存期并增强治疗效果
7. The association between clinical prognostic factors and epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) efficacy in advanced non-small-cell lung cancer patients: a retrospective assessment of 94 cases with EGFR mutations [O] . Jing-Hui Lin, Dong Lin, Ling Xu, 2016

机译：先进非小细胞肺癌患者临床预后因子和表皮生长因子受体 - 酪氨酸激酶抑制剂（EGFR-TKI）疗效的关联：EGFR突变94例回顾性评估

The association between clinical prognostic factors and epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) efficacy in advanced non-small-cell lung cancer patients: a retrospective assessment of 94 cases with EGFR mutations

摘要

著录项

相似文献

相关主题

期刊订阅